甘草酸单铵/甘氨酸/盐酸半胱氨酸(Monoammonium Glycyrrhizinate/Glycine/Cysteine Hydrochloride) - 在研适应症：慢性肝病，慢性肝炎，葡萄球菌感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Monoammonium Glycyrrhizinate/Glycine/L-Cysteine、Monoammonium Glycyrrhizinate/Glycine/L-Cysteine Hydrochloride Hydrate、AMIPHARGEN P

+ [16]

靶点-

作用机制-

治疗领域

免疫系统疾病感染消化系统疾病+ [3]

在研适应症

慢性肝病慢性肝炎葡萄球菌感染+ [9]

非在研适应症-

原研机构

NISSIN Pharmaceutical Co., Ltd.

在研机构

Towa Pharmaceutical Co., Ltd.

Nichi-Iko Pharmaceutical Co., Ltd.

Nipro Corp.

+ [3]

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1959-02-01),

湿疹肝功能不全口腔溃疡+ [2]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C42H65NO16

InChIKeyILRKKHJEINIICQ-OOFFSTKBSA-N

CAS号53956-04-0

查看全部结构式(3)

关联

1

项与甘草酸单铵/甘氨酸/盐酸半胱氨酸相关的临床试验

JPRN-UMIN000014234 / Completed

Post Marketing Study of Stronger Neo Minophagen C for Elderly Patients of Chronic Hepatitis C -Prospective Study- - Post Marketing Study of Stronger Neo Minophagen C for Elderly Patients of Chronic Hepatitis C

开始日期2011-04-01

申办/合作机构

Minophagen Pharmaceutical Co. Ltd.

100 项与甘草酸单铵/甘氨酸/盐酸半胱氨酸相关的临床结果

登录后查看更多信息

100 项与甘草酸单铵/甘氨酸/盐酸半胱氨酸相关的转化医学

登录后查看更多信息

100 项与甘草酸单铵/甘氨酸/盐酸半胱氨酸相关的专利（医药）

登录后查看更多信息

246

项与甘草酸单铵/甘氨酸/盐酸半胱氨酸相关的文献（医药）

2024-12-01·Journal of Biomechanics

Exploring the impact of breathing patterns on active drag in breaststroke swimming

Article

作者: Alves, Miriam ; Paulo Vilas-Boas, João ; Barbosa, Tiago M. ; Barbosa, Tiago M

This study aimed to compare active drag (D_a), coefficient of hydrodynamic force (C_Da) and, total external mechanical power (P_tot) between two breathing patterns in breaststroke: breathing every stroke versus every two strokes. A 6-week intervention program was conducted. Fifteen swimmers carried out two all-out bouts of 25 m using the velocity perturbation method in each breathing pattern. The study analyzed the swimmers' velocity (swimming freely and with the towed body), D_a, C_Da and P_tot. Individual data analysis revealed that 40 % of the sample experienced a decrease in D_a when breathing every two strokes, with some achieving higher velocities. Conversely, nine swimmers exhibited lower D_a values while breathing every stroke, with six of them also showing higher velocity values compared to breathing every two strokes. When comparing the pooled sample using paired t-tests, no differences were found in D_a, C_Da and, P_tot between the two breathing patterns. Furthermore, using ANCOVA analysis, results indicated that neither sex nor swimming velocity influenced the variables studied.

2024-11-01·Science of The Total Environment

Bisphenol P induces increased oxidative stress in renal tissues of C57BL/6 mice and human renal cortical proximal tubular epithelial cells, resulting in kidney injury

Article

作者: Kiyama, Ryoiti ; Liu, Yue ; Ma, Lei ; Peng, Xinyi ; Dong, Sijun ; Zhao, Lining ; Liu, Xia ; Ma, Nana ; Ma, Dan

Bisphenol P (BPP) has been detected in human biological samples; however studies on its nephrotoxicity are scarce. Given the susceptibility of kidneys to endocrine-disrupting chemicals, there is an urgent need to investigate the renal toxicity of BPP. This study aimed to evaluate the effects of different concentrations of BPPs on the kidneys of C57BL/6 mice and elucidate the underlying mechanisms of renal damage using a combination of mouse renal transcriptomic data and human renal proximal tubular epithelial cells (HK-2). Mice were exposed to BPP (0, 0.3, 30, 3000 μg/kg bw/d) via gavage for 5 weeks. Renal injury was assessed based on changes in body and kidney weights, serum renal function indices, and histopathological examination. Transcriptomic analysis identified differentially expressed genes and pathways, whereas cellular assays were used to measure cell viability, reactive oxygen species (ROS), apoptosis, and the expression of key genes and proteins. The results show that BPP exposure induces renal injury, as evidenced by increased body weight, abnormal renal function indices, and renal tissue damage. Transcriptomic analysis revealed alterations in genes and pathways related to oxidative stress, p53 signaling, autophagy, and apoptosis. Cellular experiments confirmed that BPP induces oxidative stress and apoptosis. Furthermore, BPP exposure significantly inhibits autophagy, potentially exacerbating apoptosis and contributing to kidney injury. Treatment with a ROS inhibitor (N-Acetylcysteine, NAC) mitigated BPP-induced autophagy inhibition and apoptosis, implicating oxidative stress as a key factor. BPP exposure may lead to renal injury through excessive ROS accumulation, oxidative stress, inflammatory responses, autophagy inhibition, and increased apoptosis. The effects of NAC highlight the role of oxidative stress in BPP-induced nephrotoxicity. These findings enhance our understanding of BPP-induced nephrotoxicity and underscore the need to control BPP exposure to prevent renal disease. This study emphasized the importance of evaluating the safety of new Bisphenol A analogs, including BPP, in environmental toxicology.

2024-10-01·Clinical Pharmacology & Therapeutics

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers

Article

作者: Abouir, Kenza ; Gloor, Yvonne ; Samer, Caroline Flora ; Daali, Youssef ; Exquis, Nadia

To compensate for drug response variability, drug metabolism phenotypes are determined based on the results of genetic testing, and if necessary, drug dosages are adjusted. In some cases, discrepancies between predicted and observed phenotypes (phenoconversion) may occur due to drug–drug interactions caused by concomitant medications. We conducted a prospective, exploratory study to evaluate the risk of CYP2C19 phenoconversion in genotyped healthy volunteers exposed to CYP2C19 inhibitors. Three groups of volunteers were enrolled: CYP2C19 g‐RM, g‐NM, and g‐IM (g‐ for genetically predicted). All volunteers received as CYP2C19 phenotyping substrate 10 mg omeprazole (OME) alone at the control session and in co‐administration with CYP2C19 inhibitors: voriconazole 400 mg and fluvoxamine 50 mg in second and third study sessions, respectively. Phenoconversion occurred in over 80% of healthy volunteers, with variations among genotypic groups, revealing distinct proportions in response to fluvoxamine and voriconazole. Statistically significant differences were observed in mean metabolic ratios between CYP2C19 intermediate metabolizers (g‐IMs) with *1/*2 and *2/*17 genotypes, with the *2/*17 group exhibiting lower ratios, and distinctions were noted between genotypic groups, emphasizing the impact of genetic variations on drug metabolism. When reclassified according to CYP2C19 baseline‐measured phenotype into p‐RM, p‐NM, and p‐IM (p‐ for measured phenotype), we observed 100% phenoconversion of p‐RMs and a significant phenotype switch in p‐NMs, p‐IMs, and p‐PMs after fluvoxamine and voriconazole, and complete phenoconversion of p‐IMs to p‐PMs on both inhibitors, emphasizing the impact of genetic variations on the vulnerability to CYP2C19 phenoconversion and the importance of considering both genotyping and phenotyping in predicting drug response.

1

项与甘草酸单铵/甘氨酸/盐酸半胱氨酸相关的新闻（医药）

2022-11-16

·蒲公英Ouryao

27个品规拟取消挂网资格、公示期截止11月22日！

转自：宁夏公共资源中心编辑：wangxinglai20042022年11月15日，宁夏公共资源中心发布了2022年终止挂网药品（第6批）通知，27个品规拟撤销挂网，公示期截止11月22日。通知原文各相关单位:根据《宁夏回族自治区药品阳光挂网实施细则(试行)(宁医保发[2021] 182号)要求,我中心组织开展了2022年终止挂网药品(第六批)审核工作,现将通过审核的药品予以公示。公示期:2022年11月16日至22日,共5个工作日。涉及品种：头孢泊肟酯片、枯草杆菌二联活菌肠溶胶囊、注射用胰激肽原酶、地塞米松磷酸钠注射液、硫酸庆大霉素注射液、苯妥英钠片、腺苷钴胺片、芎菊上清丸、氟尿嘧啶注射液、茶碱缓释片、红花注射液、黄瑞香注射液、阿莫西林克拉维酸钾干混悬剂、复方甘草酸单铵注射液、小儿消食片、硫酸沙丁胺醇口腔崩解片、注射用头孢西丁钠、生脉胶囊、骨筋丸片、双黄连胶囊、消朦胶囊、除障则海甫胶囊、地衣芽孢杆菌活菌颗粒、氨甲苯酸注射液、注射用奥美拉唑钠等；公示期内如有异议,请企业使用CA数字证书,登陆“宁夏医药采购平台”,进入主页“综合服务”,点击“申投诉管理”模块递交申投诉资料,逾期不予受理。联系方式:CA数字证书办理咨询电话: 4008600271转1宁夏医药采购平台技术支持: 0951-6891069区交易服务中心医药招标采购科: 0951-6891057扫描二维码查看原文2022年终止挂网药品（第六批）目录

带量采购核酸药物

100 项与甘草酸单铵/甘氨酸/盐酸半胱氨酸相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性肝病	日本	Towa Pharmaceutical Co., Ltd.	2001-01-31
慢性肝炎	日本	Nipro Corp.	2001-01-31
葡萄球菌感染	日本	Nipro Corp.	1994-07-08
肝病	日本	NISSIN Pharmaceutical Co., Ltd.	1988-09-16
药物性皮炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	1962-07-10
丘疹性荨麻疹	日本	Nichi-Iko Pharmaceutical Co., Ltd.	1962-07-10
口腔炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	1962-07-10
湿疹	日本	Minophagen Pharmaceutical Co. Ltd.	1959-02-01
肝功能不全	日本	Minophagen Pharmaceutical Co. Ltd.	1959-02-01
口腔溃疡	日本	Minophagen Pharmaceutical Co. Ltd.	1959-02-01
瘙痒	日本	Minophagen Pharmaceutical Co. Ltd.	1959-02-01
荨麻疹	日本	Minophagen Pharmaceutical Co. Ltd.	1959-02-01